BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 941 found
  Current Search:  nda: 941     

HTML
100%
Biotechs Ahead of Pharma in '08 New Drug Approvals
s the dog days of summer come to a close, it has yet to be seen whether 2008 will be a dog of a year for drug approvals, as was 2007, with only 16 new molecular entities (NME) and two new biologics approved last year - the lowest number of...
Macro World Investor:  Aug 29 2008 11:23PM
Matching: nda
Find similar documents
HTML
100%
Biotechs Ahead of Pharma in '08 New Drug Approvals
s the dog days of summer come to a close, it has yet to be seen whether 2008 will be a dog of a year for drug approvals, as was 2007, with only 16 new molecular entities (NME) and two new biologics approved last year - the lowest number of...
Calibre Macro World:  Aug 29 2008 10:55PM
Matching: nda
Find similar documents
HTML
100%
BioDelivery Sciences Anticipates First Half 2009 Approval of BEMA Fentanyl (ONSOLIS)
RALEIGH, N.C.--(BUSINESS WIRE)--Aug.

28, 2008 - BioDelivery Sciences International, Inc.

(Nasdaq:BDSI) today announced receipt of a Complete Response letter from the U.S.

Food and Drug Administration (FDA) regarding the Company's New...

Pharma Live:  Aug 29 2008 1:41AM
Matching: nda
Find similar documents
HTML
100%
USPTO Backlog Impacts Biopharma Industry
Unless Situation Is Resolved, Investment in New Candidates May Be Delayed or Withheld Anthony Tridico Jim Kastenmayer Ali Kargbo Large pharmaceutical companies are increasingly turning to smaller biotechnology and pharmaceutical companies to...
Genetic Engineering News:  Aug 29 2008 8:08AM
Matching: nda
Find similar documents
HTML
100%
Somaxon Pharmaceuticals to Present at the Thomas Weisel 2008 Healthcare Conference and NewsMakers in the Biote
SAN DIEGO-- (BUSINESS WIRE) -- Somaxon Pharmaceuticals, Inc.

(NASDAQ:SOMX) today announced that Richard Pascoe, the companys recently named president and chief executive officer, will present a company update at the Thomas Weisel 2008...

SmartBrief:  Aug 29 2008 12:16PM
Matching: nda
Find similar documents
HTML
100%
FDA Grants IND For Pro-Pharmaceuticals' DAVANAT® To Treat Breast Cancer Patient
NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc.

(Amex: PRW), today announced that the U.S.

Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of DAVANAT in combination with 5-FU...

Pharmaceutical Online:  Aug 29 2008 5:08AM
Matching: nda
Find similar documents
HTML
100%
Somaxon Pharmaceuticals to Present at the Thomas Weisel 2008 Healthcare Conference and NewsMakers in the Biote
SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc.

(NASDAQ:SOMX - News) today announced that Richard Pascoe, the companys recently named president and chief executive officer, will present a company update at the Thomas Weisel 2008...

Business Wire via Yahoo!:  Aug 29 2008 12:14AM
Matching: nda
Find similar documents
HTML
100%
FDA Grants IND for Pro-Pharmaceuticals' DAVANAT to Treat Breast Cancer Patient
Pro-Pharmaceuticals, Inc.

has been granted an Investigational New Drug (IND) application by the FDA for use of DAVANAT in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky.

DAVANAT...

PharmaceuticalProcessing:  Aug 28 2008 11:38PM
Matching: nda
Find similar documents
HTML
100%
IDM PHARMA INC EPS Estimated At -1.33: Current Recommendation is Buy
Company: IDM PHARMA INC Report Headline: 'Mifamurtide NDA Amendment Expected 1Q:08 Following FDA's Not Approvable Letter' Report Date: August 27, 2007 Current FY EPS Estimate [FY2007]: -1.33 Previous EPS Estimate for Current FY [FY2007...
Calibre Macro World:  Aug 29 2008 8:07PM
Matching: nda
Find similar documents
HTML
100%
IDM PHARMA INC EPS Estimated At -1.33: Current Recommendation is Buy
Company: IDM PHARMA INC Report Headline: 'Mifamurtide NDA Amendment Expected 1Q:08 Following FDA's Not Approvable Letter' Report Date: August 27, 2007 Current FY EPS Estimate [FY2007]: -1.33 Previous EPS Estimate for Current FY [FY2007...
Macro World Investor:  Aug 29 2008 8:03PM
Matching: nda
Find similar documents
HTML
100%
Novartis to take $235 million charge as Aurograb fails
Novartis says that it is ending development of the antibacterial Aurograb after it failed to show efficacy in mid-stage trials.

The lack of efficacy was revealed following a review of a Phase II study of Aurograb, an add-on therapy to...

Pharma Times:  Aug 29 2008 10:11AM
Matching: nda
Find similar documents
HTML
100%
Napo Pharmaceuticals H1 loss widens as co says funding essential to survive
LONDON (Thomson Financial) - Napo Pharmaceuticals Inc.

(News) reported deepening losses for the first half of 2008 and said that, unless it raises more funds, its future is in jeopardy.

The group, which focuses on bringing proprietary...

FinanzNachrichten.de:  Aug 29 2008 8:42AM
Matching: nda
Find similar documents
HTML
100%
Napo Pharmaceuticals H1 loss widens as co says funding essential to survive
LONDON (Thomson Financial) - Napo Pharmaceuticals Inc.

reported deepening losses for the first half of 2008 and said that, unless it raises more funds, its future is in jeopardy.

The group, which focuses on bringing proprietary products...

Sharewatch:  Aug 29 2008 8:22AM
Matching: nda
Find similar documents
HTML
100%
Pain Therapeutics, King Pharma develop abuse-resistant pain medication
Pain Therapeutics, Inc.

and King Pharmaceuticals, Inc.

announced they are developing a new abuse-resistant prescription pain medication called PTI-721.

Like Remoxy (controlled-release oxycodone), PTI-721's patented formulation is...

PharmaBiz:  Aug 29 2008 8:18AM
Matching: nda
Find similar documents
HTML
100%
FDA Asks for More Information Before Sanctioning J&JPRDs Drug for Hospital-Acquired Pneum
Johnson & Johnson Pharmaceutical Research & Development(J&JPRD) reports that the FDA requires additional data to approve Doribax for hospital-acquired pneumonia, or nosocomial pneumonia (NP), including ventilator...
Genetic Engineering News:  Aug 29 2008 4:07AM
Matching: nda
Find similar documents
HTML
100%
Somaxon Pharmaceuticals to Present at the Thomas Weisel 2008 Healthcare Conference and NewsMakers in the
- Somaxon Pharmaceuticals, Inc.

(NASDAQ:SOMX) today announced that Richard Pascoe, the company's recently named president and chief executive officer, will present a company update at the Thomas Weisel 2008 Healthcare Conference on...

PR inside:  Aug 29 2008 12:15AM
Matching: nda
Find similar documents
HTML
100%
Barr receives U.S. approval for generic Razadyne tablets
Barr Pharmaceuticals, Inc.

today announced that its subsidiary, , received final approval from the U.S.

Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne (galantamine...

News-Medical.Net:  Aug 28 2008 10:55PM
Matching: nda
Find similar documents
HTML
100%
FDA grants IND for Davanat to treat breast cancer patient
Pharmaceutical News Pro-Pharmaceuticals, Inc.

has announced that the U.S.

Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer...

News-Medical.Net:  Aug 28 2008 10:39PM
Matching: nda
Find similar documents
HTML
100%
POZEN, Inc. Q2 2008 Earnings Call Transcript
Including our inability to know with certainty what standards the FDA will use to evaluate drug candidates and how that may change or evolve over time, how the FDA evaluates data, what the results of future trials may be, whether those...
Seeking Alpha:  Aug 28 2008 12:51AM
Matching: nda
Find similar documents
HTML
100%
BioDelivery Sciences Anticipates First Half 2009 Approval of BEMA(TM) Fentanyl (ONSOLIS(TM))
RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc.

(Nasdaq:BDSI - News) today announced receipt of a Complete Response letter from the U.S.

Food and Drug Administration (FDA) regarding the Companys New Drug...

Yahoo!:  Aug 28 2008 12:41PM
Matching: nda
Find similar documents
HTML
100%
NexMed Shares Fall Hard as Novartis Nixes NDA
Stock Drops More Than 80 Percent NexMed Inc.

shares plummeted 81.6 percent Wednesday on news that its partner, Novartis AG, has decided that, for now, it will not file a new drug application for a topical nail fungus product that uses...

Macro World Investor:  Aug 28 2008 12:16AM
Matching: nda
Find similar documents
HTML
100%
NexMed Shares Fall Hard as Novartis Nixes NDA
NexMed Inc.

shares plummeted 81.6 percent Wednesday on news that its partner, Novartis AG, has decided that, for now, it will not file a new drug application for a topical nail fungus product that uses NexMed's drug delivery technology.

Calibre Macro World:  Aug 27 2008 11:45PM
Matching: nda
Find similar documents
HTML
100%
FDA Grants IND for Pro-Pharmaceuticals' DAVANAT(R) to Treat Breast Cancer Patient
Pro-Pharmaceuticals, Inc.

(PRW), today announced that the U.S.

Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of DAVANAT in combination with 5-FU to treat a breast cancer patient at...

Houston Chronicle:  Aug 28 2008 12:24PM
Matching: nda
Find similar documents
HTML
100%
FDA Grants IND for Pro-Pharmaceuticals' DAVANAT(R) to Treat Breast Cancer Patient
, 7:00 AM EST News source: Business Wire Pro-Pharmaceuticals, Inc.

(Amex: PRW), today announced that the U.S.

Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of DAVANAT(R) in...

Genetic Engineering News:  Aug 28 2008 11:52AM
Matching: nda
Find similar documents
HTML
100%
FDA Grants IND for Pro-Pharmaceuticals' Davanat to Treat Breast Cancer Patient
- Pro-Pharmaceuticals, Inc.

(Amex: PRW), today announced that the U.S.

Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of DAVANAT(R) in combination with 5-FU to treat a breast cancer...

Pharma Live:  Aug 28 2008 11:49AM
Matching: nda
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.